Kathryn Welch, PA
Medical · Wichita, KSNPI 1336142116
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,795 of the $32,055 with a category attached, or 77.4%. Livanova USA, Inc. accounts for 94.6% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $12,400, more than ten times the $811 reported in 2021. Among medical clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $139.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$30K
- Supernus Pharmaceuticals, Inc.$149
- Acadia Pharmaceuticals Inc$148
- UCB, Inc.$134
- Jazz Pharmaceuticals Inc.$119
- Neurelis, Inc.$104
- plus $1K from 28 others
What the payments were for
- Speaking & faculty fees$24,79577%
- Travel & lodging$2,1027%
- Food & beverage$5,12816%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 139 | $30,326 |
| Supernus Pharmaceuticals, Inc. | 18 | $149 |
| Acadia Pharmaceuticals Inc | 2 | $148 |
| UCB, Inc. | 7 | $134 |
| Jazz Pharmaceuticals Inc. | 6 | $119 |
| Neurelis, Inc. | 5 | $104 |
| Biogen | 5 | $95 |
| NS Pharma, Inc. | 4 | $85 |
| SK Life Science, Inc. | 4 | $80 |
| Amneal Pharmaceuticals LLC | 3 | $78 |
| ITF Therapeutics LLC | 3 | $68 |
| Genentech USA, Inc. | 5 | $64 |
| Biohaven Pharmaceuticals, Inc. | 3 | $58 |
| Sarepta Therapeutics, Inc. | 3 | $57 |
| Catalyst Pharmaceuticals, Inc. | 2 | $46 |
| Ironshore Pharmaceuticals Inc. | 2 | $40 |
| Astellas Pharma US Inc | 1 | $37 |
| Amgen | 1 | $33 |
| Greenwich Biosciences, Inc. | 2 | $32 |
| Biocodex, Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Aquestive Therapeutics, Inc. | 1 | $23 |
| Mirum Pharmaceuticals, Inc. | 1 | $22 |
| Zogenix Inc. | 1 | $21 |
| Metacel Pharmaceuticals LLC | 1 | $21 |
| Immedica Pharma US, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Corium, LLC | 1 | $17 |
| Aucta Pharmaceuticals, Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$25,788
- VNS Therapy$2,172
- DAYBUE$123
How this compares
$32,055 in reported general payments places this provider in the 95th percentile of 205 medical providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 167 | $26,976 |
| ValtocoDiazepam | 18 | $20,903 |
| XcopriCenobamate | 17 | $18,167 |
| NayzilamMidazolam | 26 | $17,965 |
| Lacosamide | 107 | $14,660 |
| Levetiracetam | 189 | $9,482 |
| Carbamazepine ErCarbamazepine | 73 | $9,346 |
| Clobazam | 58 | $9,193 |
| Methylphenidate ErMethylphenidate Hcl | 42 | $6,641 |
| Felbamate | 18 | $4,932 |
| Divalproex Sodium | 54 | $4,402 |
| Carbamazepine | 42 | $4,221 |
| Divalproex Sodium ErDivalproex Sodium | 48 | $3,929 |
| Lamotrigine | 189 | $3,761 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $3,515 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurelis, Inc.Valtoco | $104 | $20,90318 claims |
| SK Life Science, Inc.Xcopri | $80 | $18,16717 claims |
| UCB, Inc.Nayzilam | $134 | $17,96526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 205 medical providers in Kansas.
Other medical in Wichita
- Richard AllenbachWichita$70K
- Jason MengesWichita$15K
- Trang BrownleeWichita$11K
- Susan GeorgeWichita$10K
- Andrew OsbeckWichita$9K
- Lisa HarrisWichita$8K
- Christiane YourdonWichita$6K
- Kristen OchsnerWichita$5K
- Kristen WolfWichita$5K
- Christine JohnsonWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.